A comprehensive approach to treating chronic recurrent uncomplicated cystitis during pregnancy


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Objective: To evaluate the eff iciency of combination therapy for chronic recurrent uncomplicated cystitis during pregnancy. Materials and methods: The investigation enrolled 50 pregnant women with chronic recurrent uncomplicated cystitis in the second or third trimester. There were two equal formed groups: 1) a study group that included 25 women who received combination treatment with an antibiotic and an immunomodulatory agent; 2) a comparison group that consisted of 25 women who took an antibiotic only. The efficiency of different treatment regimens for chronic recurrent uncomplicated cystitis was evaluated, by analyzing laboratory data, assessing the Acute Cystitis Symptom Score (ACSS) questionnaire, determining the immune status, and analyzing the characteristics of the course of labor and perinatal outcomes. Results: Therapy with an antibiotic in combination with the immunomodulatory agent Superlymph showed the greatest efficiency in treating chronic recurrent uncomplicated cystitis. In the study group, leukocytosis during a urinalysis and the growth of pathogens during microscopic examination were most significantly decreased; positive changes in the indicators of innate immunity were more pronounced; the period between exacerbations of cystitis was much longer and the duration of relapses was shorter; and the quality of life became substantially better, as shown by the ACSS questionnaire. In addition, this patient cohort was recorded to have the most favorable obstetric and perinatal outcomes. Conclusion: The immunomodulatory agent Superlymph in combination with an antibiotic can be recommended for use in the therapy of chronic recurrent uncomplicated cystitis in the second or third trimester of pregnancy, which signif icantly increases the eff iciency of the performed treatment.

Texto integral

Acesso é fechado

Sobre autores

Victor Tyutyunnik

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: tioutiounnik@mail.ru
Professor, MD, PhD, Leading Researcher of Research and Development Service

Olga Mikhailova

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: omikhaylova@gmail.com
PhD, Researcher, 2 Maternity Department

Natalia Kan

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: kan-med@mail.ru
Professor, MD, PhD, Deputy Director for Science

Dzhamilia Mirzabekova

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: jamilyal705@yandex.ru
graduate student

Bibliografia

  1. Министерство здравоохранения Российской Федерации. Цистит у женщин. Клинические рекомендации (протокол лечения). М.; 2021. 59 с.
  2. Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю., ред. Урология. Российские клинические рекомендации. M.: ГЭОТАР-Медиа; 2016. 496 с.
  3. Министерство здравоохранения Российской Федерации. Инфекция мочевых путей при беременности. Клинические рекомендации. М.; 2021. 47с.
  4. Kolman K.B. Cystitis and pyelonephritis: diagnosis, treatment, and prevention. Prim. Care. 2019; 46(2): 191-202. https://dx.doi.org/10.1016/j.pop.2019.01.001.
  5. Ny S., Edquist P., Dumpis U., Grondahl-Yli-Hannuksela K., Hermes J., Kling A.M. et al.; NoDARS UTIStudy Group. Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia. J. Glob. Antimicrob. Resist. 2019; 17: 25-34. https://dx.doi.org/10.1016/j.jgar.2018.11.004.
  6. Flores-Mireles A.L., Walker J.N., Caparon M., Hultgren S.J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 2015; 13(5): 269-84. https://dx.doi.org/10.1038/nrmicro3432.
  7. Shang Y.J., Wang Q.Q., Zhang J.R., Xu Y.L., Zhang ЖЖ, Chen Y. et al. Systematic review and meta-analysis of flow cytometry in urinary tract infection screening. Clin. Chim. Acta. 2013; 424: 90-5. https://dx.doi.org/10.1016/j.cca.2013.05.014.
  8. Apodaca G. The uroepithelium: not just a passive barrier. Traffic. 2004; 5(3): 117-28. https://dx.doi.org/10.1046/j.1600-0854.2003.00156.x.
  9. Glaser A.P., Schaeffer A.J. Urinary tract infection and bacteriuria in pregnancy. Urol. Clin. North Am. 2015; 42(4): 547-60. https://dx.doi.org/10.1016/j.ucl.2015.05.004.
  10. Pietrucha-Dilanchian P., Hooton T.M. Diagnosis, Treatment, and Prevention of Urinary Tract Infection. Microbiol Spectr. 2016; 4(6). https://dx.doi.org/10.1128/microbiolspec.UTI-0021-2015.
  11. Henderson J.T., Webber E.M., Bean S.I. Screening for asymptomatic bacteriuria in adults: An updated systematic review for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); Sep. 2019. Report No.: 19-05252-EF-1.
  12. Schneeberger C., Geerlings S.E., Middleton P., Crowther C.A. Interventions for preventing recurrent urinary tract infection during pregnancy. Cochrane Database Syst. Rev. 2015; 2015(7): CD009279. https://dx.doi.org/10.1002/14651858. CD009279.pub3.
  13. Kazemier B.M., Koningstein F.N., Schneeberger C., Ott A., Bossuyt P.M., de Miranda E. et al. Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomized controlled trial. Lancet Infect. Dis. 2015; 15(11): 1324 33. https://dx.doi.org/10.1016/S1473-3099(15)00070-5
  14. Smaill F.M., Vazquez J.C. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst. Rev. 2019; 2019(11): CD000490. https://dx.doi.org/10.1002/14651858.CD000490.
  15. Ghouri F., Hollywood A., Ryan K. A systematic review of non-antibiotic measures for the prevention of urinary tract infections in pregnancy. BMC Pregnancy Childbirth. 2018; 18(1): 99. https://dx.doi.ois/10.1186/s12884-018-1732-2.
  16. Choe H.S., Lee S.J., Yang S.S., Hamasuna R., Yamamoto S., Cho Y.H., Matsumoto T.; Committee for Development of the UAA-AAUS Guidelines for UTI and STI. Summary of the UAA-AAUS guidelines for urinary tract infections. Int. J. Urol. 2018; 25(3): 175-85. https://dx.doi.org/10.1111/iju.13493.
  17. Балушкина А.А., Кан Н.Н., Тютюнник В.Л. Современный взгляд на терапию инфекций мочевыводящих путей у беременных. РМЖ. Медицинское обозрение. 2018; 2[8(1)]: 37-40.
  18. Gonzalez E.J., Arms L., Vizzard M.A. The role(s) of cytokines/chemokines in urinary bladder inflammation and dysfunction. Biomed. Res. Int. 2014; 2014: 120525. https://dx.doi.org/10.1155/2014/120525.
  19. Аполихина И.А., Саидова А. С., Тетерина Т.А. Эффективность применения локальной цитокинотерапии в комплексном лечении пациенток с хроническим циститом. Акушерство и гинекология. 2019; 12: 167-72. у беременных с дисплазией шейки матки. Русский медицинский журнал. Мать и дитя. 2019; 2(3): 173-6. https://dx.doi.org/10.18565/aig.2019.12.167-172.
  20. Kalinderi K., Delkos D., Kalinderis M., Athanasiadis A., Kalogiannidis I. Urinary tract infection during pregnancy: current concepts on a common multifaceted problem. J. Obstet. Gynaecol. 2018; 38(4): 448-53.https://dx.doi.org/10.1080/01443615.2017.1370579.
  21. Боровкова Е.И., Залесская С.А., Степанянц И.В. Сравнительная эффективность влагалищного и ректального применения цитокинотерапии у беременных с дисплазией шейки матки. Русский медицинский журнал. Мать и дитя. 2019; 2(3): 173-6. https://dx.doi.org/10.32364/2618-8430-2019-2-3-173-176.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2022

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies